Cancer/testis antigen 1 (80-88)

Cancer/testis antigen 1 (80-88) is a synthetic peptide fragment derived from the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1, which is recognized for its restricted expression pattern in normal adult tissues and frequent upregulation in a wide range of malignancies. The 80-88 peptide sequence represents a defined epitope within the CTAG1 protein, making it highly relevant for immunological research, especially in the context of tumor immunology and antigen-specific immune response studies. Due to its immunogenic properties and its association with tumor-specific expression, this peptide serves as a valuable tool for dissecting the molecular mechanisms of antigen recognition, T-cell activation, and epitope mapping in cancer research laboratories.

Epitope mapping: Cancer/testis antigen 1 (80-88) is widely employed in epitope mapping studies to delineate the precise regions of CTAG1 recognized by cytotoxic T lymphocytes (CTLs). By using this defined peptide fragment in conjunction with patient-derived or engineered T cells, researchers are able to characterize the immunodominant epitopes that can elicit robust immune responses. This approach is essential for understanding the specificity and breadth of anti-tumor T-cell responses, which informs the selection of peptide candidates for further immunological investigation or translational research.

T-cell activation assays: The 80-88 peptide is instrumental in functional assays designed to assess the activation, proliferation, and cytokine production of T cells specific for CTAG1. By pulsing antigen-presenting cells with this peptide, investigators can monitor T-cell receptor (TCR) engagement, downstream signaling events, and effector functions. Such assays provide critical insights into the immunogenicity of the epitope and support the evaluation of T-cell responses in preclinical models or ex vivo human samples.

Vaccine research: As a well-characterized immunogenic epitope, the Cancer/testis antigen 1 (80-88) peptide is frequently utilized in the development and optimization of experimental cancer vaccines. Its inclusion in peptide-based vaccine formulations allows for the targeted stimulation of antigen-specific CTLs, enabling researchers to evaluate the immunopotency and safety profiles of candidate immunogens. The use of this peptide in vaccine design studies also facilitates the investigation of adjuvants, delivery systems, and epitope combinations that may enhance anti-tumor immunity.

MHC binding studies: The defined sequence of the 80-88 epitope supports its application in major histocompatibility complex (MHC) binding assays. Researchers use this peptide to determine its affinity for various HLA alleles, assess peptide-MHC stability, and model peptide presentation on the cell surface. These studies are essential for predicting epitope immunogenicity, understanding antigen processing pathways, and guiding the rational selection of peptides for immunotherapeutic strategies.

Immunomonitoring: The Cancer/testis antigen 1 (80-88) peptide is a valuable reagent in immunomonitoring protocols that track the presence and functional status of antigen-specific T cells in research samples. By incorporating the peptide into ELISPOT, multimer staining, or intracellular cytokine staining assays, scientists can quantify the frequency and phenotype of CTAG1-reactive T cells in peripheral blood or tumor-infiltrating lymphocyte populations. Such monitoring is crucial for evaluating immune responses in experimental systems and validating the efficacy of immunomodulatory interventions targeting CTAG1.

1. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

2. Cationic cell-penetrating peptides are potent furin inhibitors

3. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

4. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide

5. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury